1,340 results on '"Okita, Kiwamu"'
Search Results
2. REFLECT—a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset
3. Clinical features of liver cirrhosis patients with muscle cramping: a multicenter study
4. Supplementary Figure 1 from Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma
5. Nutritional Therapy in Patients with Liver Cirrhosis
6. Strategy for the Development of Cell Therapy Using Bone Marrow Cells to Repair Damaged Liver
7. Response criteria of tolvaptan for the treatment of hepatic edema
8. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma
9. HHM: A Dominant Inhibitory Helix-Loop-Helix Protein Associated with Liver-Specific Gene Expression and Liver Stem Cells
10. Inhibitory Effects of the Herbal Medicine Sho-saiko-to on Liver Fibrosis
11. Prevention of Hepatocarcinogenesis by Fibrosuppression
12. Risk Factors for Hepatocellular Carcinoma Among Chronic Hepatitis C Patients Treated with Interferon
13. Different Quasispecies of Hepatitis C Virus in Human Serum, Peripheral Blood Mononuclear Cells, and Liver
14. Safety and effectiveness of sorafenib in Japanese patients with hepatocellular carcinoma in daily medical practice: interim analysis of a prospective postmarketing all-patient surveillance study
15. Impact of bodyweight‐based starting doses on the safety and efficacy of lenvatinib in primarily Japanese patients with hepatocellular carcinoma
16. Anti-Fibrotic Agent Reduces Enzyme-Altered Lesions and Neoplasms in the Rat Liver
17. Can serum albumin level affect the pharmacological action of tolvaptan in patients with liver cirrhosis? A post hoc analysis of previous clinical trials in Japan
18. Survey of survival among patients with hepatitis C virus-related hepatocellular carcinoma treated with peretinoin, an acyclic retinoid, after the completion of a randomized, placebo-controlled trial
19. Clinical characteristics, treatment, and prognosis of non-B, non-C hepatocellular carcinoma: a large retrospective multicenter cohort study
20. Peretinoin after curative therapy of hepatitis C-related hepatocellular carcinoma: a randomized double-blind placebo-controlled study
21. The Usefulness of the Athens Insomnia Scale for Evaluating Sleep Disturbance in Patients with Chronic Liver Disease Comparing with Pittsburgh Sleep Quality Index and Epworth Sleepiness Scale
22. Experimental Hepatocarcinogenesis and Its Prevention
23. Efficient detection of hepatocellular carcinoma by a hybrid blood test of epigenetic and classical protein markers
24. Phase 1 and pharmacological trial of OPB-31121, a signal transducer and activator of transcription-3 inhibitor, in patients with advanced hepatocellular carcinoma
25. Present status of immunotherapy of hepatocellular carcinoma
26. Proposal for new sleep disorder criteria in patients with chronic liver disease: Influence of liver‐related complications
27. Clinical effectiveness of bipolar radiofrequency ablation for small liver cancers
28. Giant cavernous hepatic hemangioma shrunk by use of sorafenib
29. A randomized phase II trial of intra-arterial chemotherapy using SM-11355 (Miriplatin) for hepatocellular carcinoma
30. Timeline for development of autologous bone marrow infusion (ABMi) therapy and perspective for future stem cell therapy
31. The efficacy and safety of terlipressin and albumin in patients with type 1 hepatorenal syndrome: a multicenter, open-label, explorative study
32. A multicenter, open-label, dose-ranging study to exploratively evaluate the efficacy, safety, and dose–response of tolvaptan in patients with decompensated liver cirrhosis
33. Correlation between changes in bodyweight and changes in ascites volume in liver cirrhosis patients with hepatic edema in short-term diuretic therapy
34. Clinical efficacy of combination therapy with ME3738 and pegylated interferon-alpha-2a in patients with hepatitis C virus genotype 1
35. Use of entecavir to prevent hepatitis B virus reactivation during cytotoxic chemotherapy for solid malignancy
36. Tolvaptan for improvement of hepatic edema: A phase 3, multicenter, randomized, double-blind, placebo-controlled trial
37. Dose-finding trial of tolvaptan in liver cirrhosis patients with hepatic edema: A randomized, double-blind, placebo-controlled trial
38. Impact of bodyweight (BW)-based starting doses on safety and efficacy of lenvatinib (LEN) in patients (pts) with hepatocellular carcinoma (HCC).
39. Proposal of Stroop test cut‐off values as screening for neuropsychological impairments in cirrhosis: A Japanese multicenter study
40. Analysis of hepatitis A virus protein 2B in sera of hepatitis A of various severities
41. A modified Japan Integrated Stage score for prognostic assessment in patients with hepatocellular carcinoma
42. A large-scale, multicentre, double-blind trial of ursodeoxycholic acid in patients with chronic hepatitis C
43. Hepatitis C virus core protein inhibits deoxycholic acid-mediated apoptosis despite generating mitochondrial reactive oxygen species
44. Fibroblast growth factor 2 facilitates the differentiation of transplanted bone marrow cells into hepatocytes
45. Management of hepatocellular carcinoma in Japan
46. BCAA-enriched snack improves nutritional state of cirrhosis
47. Development of cell therapy using autologous bone marrow cells for liver cirrhosis
48. Usefulness of endoscopic ultrasound-guided fine-needle aspiration biopsy for the diagnosis of pancreatic cancer
49. In situ detection of oxidized n-3 polyunsaturated fatty acids in chronic hepatitis C: correlation with hepatic steatosis
50. D-Penicillamine improved laparoscopic and histological findings of the liver in a patient with Wilson’s disease: 3-year follow-up after diagnosis of Coombs-negative hemolytic anemia of Wilson’s disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.